Table 1.

Selected clinical trials of single-agent immunotherapy for HCC.

	Drug	Trial ID	Phase	N	Population	mOS	ORR	Reference
ICI	Nivolumab	NCT01658878	I/II	214	Advanced HCC	13.8	20%	[39]
		NCT02576509	III	371	Advanced HCC	16.4	15.4%	[40]
	Pembrolizumab	NCT02702414	II	104	Advanced HCC	12.9	17.3%	[41]
	Camrelizumab	NCT02989922	II	217	Advanced HCC	N/A	14.7%	[43]
	Tremelimumab	NCT02519348	I/II	69	Unresectable HCC	15.1	7.2%	[45]
Oncolytic virus	Pexa-Vec	NCT00554372	II	30	Unresectable HCC	6.7 (low dose), 14.1 (high dose),	15%	[46]
Vaccine	Ilixadencel	NCT01974661	I	11	Advanced HCC	2.7 (first-line), 10.9 (second-line)	N/A	[47]

6ORR, objective response rate; mOS, median overall survival (months); N/A, not available.